Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $100M
Founded date: 2019
Investors 10
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.01.2022 | - | $30M | - |
| 28.09.2021 | Series A | $70M | RA Capital... |
Mentions in press and media 19
| Date | Title | Description |
| 02.09.2026 | Psilocybin, LSD Hallucination Fingerprint Identified: Cell Test Bypasses Animal Screens | By Jackie Manning Published: Sep 02 2026, 9:40 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 13.12.2023 | Health | New psychedelic-like drugs: All treatment, no trip? | Since their creation decades ago, mind-altering drugs have remained as unchanged as bellbottoms, tie-dye and patchouli oil. Now — full of promise and peril — psychedelics are undergoing a makeover. Chemical neuroscientists, many based in No... |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industry, according to top investors | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; Jackie von Salm, a cofounder and the CSO of Psilera; Jimmy Qian, a cofounder and the president of Osmind. Sherry Rais/Enthea; Mark Rus/Delix... |
| 22.11.2022 | Only a handful of psychedelics companies have gotten funding from established biotech investors. Here's what they've done right, according to a top VC. | Andrew Levin is partner and managing director at VC firm RA Capital and interim CEO of Lusaris. RA Capital This story is available exclusively to Insider subscribers. Become an Insider and start reading now. RA Capital is one of the few mai... |
| 11.01.2022 | Delix Therapeutics Closes $30M Convertible Note Financing | Delix Therapeutics, a Boston MA-based neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, raised $30M in Convertible Note funding. Primarily led by existing investors, funding wa... |
| 10.01.2022 | Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank | BOSTON, Jan. 10, 2022 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced that it closed over $30 ... |
| 28.09.2021 | Delix Therapeutics closes $70M Series A | Delix Therapeutics has raised $70 million in a round co-led by Artis Ventures, RA Capital Management and OMX Ventures. Delix is developing neuroplasticity-promoting therapeutics for patients suffering from mental health disorders. Select Ad... |
| 28.09.2021 | Delix Therapeutics Raises $70M in Series A Funding | Delix Therapeutics, a Boston MA-based preclinical neuroscience company, raised $70M in Series A funding. The round was led by Artis Ventures, RA Capital Management, and founding investor OMX Ventures, with participation from Apeiron, Bail C... |
| 28.09.2021 | Daily funding roundup - September 27, 2021 | Dice raised $122M; Delix Therapeutics landed $70M; Astera Labs secured $50M Dice: Dice is a London-based live event discovery and booking platform. Dice has raised $122 million in Series C funding led by SoftBank, with participation from Fu... |
| 27.09.2021 | Delix Therapeutics : Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders | BOSTON, Sept. 27, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix Therapeutics (the "Company"), today announced the closing of a $70 million Series A financing round. The round was led by ARTIS Ventures, RA Capital Man... |
Show more